Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(1.97)
# 2,994
Out of 4,931 analysts
59
Total ratings
27.87%
Success rate
-0.99%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Assumes: Buy | $29 | $9.05 | +220.44% | 1 | Aug 7, 2025 | |
| INDV Indivior | Initiates: Buy | $28 | $22.05 | +26.98% | 1 | Aug 6, 2025 | |
| ENTA Enanta Pharmaceuticals | Assumes: Buy | $20 | $6.99 | +186.12% | 1 | Jul 28, 2025 | |
| MNKD MannKind | Assumes: Buy | $9 | $3.43 | +162.39% | 2 | Jul 16, 2025 | |
| ANIP ANI Pharmaceuticals | Initiates: Buy | $84 | $69.01 | +21.72% | 4 | Jul 10, 2025 | |
| ZVRA Zevra Therapeutics | Initiates: Buy | $26 | $12.13 | +114.34% | 1 | Jul 2, 2025 | |
| CRMD CorMedix | Initiates: Buy | $20 | $10.81 | +85.01% | 2 | Jun 30, 2025 | |
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $12 | $5.39 | +122.84% | 2 | Jun 26, 2025 | |
| CNTB Connect Biopharma Holdings | Assumes: Buy | $7 | $2.07 | +238.16% | 1 | Jun 12, 2025 | |
| PYPD PolyPid | Maintains: Buy | $11 → $13 | $3.21 | +304.98% | 3 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.84 | +226.09% | 2 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $5 | $1.51 | +231.13% | 2 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.08 | +733.33% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.30 | +187.67% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $0.98 | +410.20% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.64 | +354.55% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $3.78 | +138.41% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.39 | +1,967.18% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $8.24 | +94.17% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.53 | +1,776.17% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $15.87 | +2,767.04% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $24.36 | +142.20% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $112.08 | +60.60% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.37 | +5,796.54% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $7.30 | +23.29% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $26.60 | +20.32% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.17 | +1,880,241.88% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $32.94 | -33.21% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $15.23 | +228.30% | 1 | Jul 12, 2018 |
Sagimet Biosciences
Aug 7, 2025
Assumes: Buy
Price Target: $29
Current: $9.05
Upside: +220.44%
Indivior
Aug 6, 2025
Initiates: Buy
Price Target: $28
Current: $22.05
Upside: +26.98%
Enanta Pharmaceuticals
Jul 28, 2025
Assumes: Buy
Price Target: $20
Current: $6.99
Upside: +186.12%
MannKind
Jul 16, 2025
Assumes: Buy
Price Target: $9
Current: $3.43
Upside: +162.39%
ANI Pharmaceuticals
Jul 10, 2025
Initiates: Buy
Price Target: $84
Current: $69.01
Upside: +21.72%
Zevra Therapeutics
Jul 2, 2025
Initiates: Buy
Price Target: $26
Current: $12.13
Upside: +114.34%
CorMedix
Jun 30, 2025
Initiates: Buy
Price Target: $20
Current: $10.81
Upside: +85.01%
Eupraxia Pharmaceuticals
Jun 26, 2025
Initiates: Buy
Price Target: $12
Current: $5.39
Upside: +122.84%
Connect Biopharma Holdings
Jun 12, 2025
Assumes: Buy
Price Target: $7
Current: $2.07
Upside: +238.16%
PolyPid
Jun 9, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $3.21
Upside: +304.98%
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $1.84
Upside: +226.09%
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.51
Upside: +231.13%
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.08
Upside: +733.33%
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $7.30
Upside: +187.67%
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.98
Upside: +410.20%
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $2.64
Upside: +354.55%
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.78
Upside: +138.41%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.39
Upside: +1,967.18%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $8.24
Upside: +94.17%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.53
Upside: +1,776.17%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $15.87
Upside: +2,767.04%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $24.36
Upside: +142.20%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $112.08
Upside: +60.60%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.37
Upside: +5,796.54%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $7.30
Upside: +23.29%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $26.60
Upside: +20.32%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.17
Upside: +1,880,241.88%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $32.94
Upside: -33.21%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $15.23
Upside: +228.30%